Literature DB >> 9789709

Poor visual discrimination and visual hallucinations in Parkinson's disease.

N J Diederich1, C G Goetz, R Raman, E J Pappert, S Leurgans, V Piery.   

Abstract

This study examined the relationship between deficits in color and contrast discrimination and visual hallucinations (VH) in patients with Parkinson's disease (PD) and normal visual acuity. Thirty-five nondemented and nonpsychotic PD patients with normal visual acuity and without major ophthalmologic disease were interviewed twice and divided into two groups: hallucinators (n = 14) and non-hallucinating controls (n = 21). The groups were compared for color vision (assessed by Lanthony D-15 [LD] and Farnsworth-Munsell 100 hue [FM] tests), and for contrast sensitivity (tested by Vis tech tables [VT] and monocular and binocular Pelli-Robson test [PR]). There was no difference in age, duration or stage of PD, or dosage or duration of levodopa therapy between the two groups. Parkinson's disease patients showed impairment on all visual tests, with the hallucinators performing worse than the controls on all tests. This difference was significant for the LD (p < 0.007), the VT at 1.5 and 3 cycles per degree (p < 0.037 and 0.043, respectively) and the monocular PR tests (p < 0.049). The results led the authors to conclude that in patients with normal visual acuity, those with VH show added visual deficits of color and contrast discrimination. These ophthalmopathies may therefore be facilitating factors for visual hallucinations in PD and justify more focused research on the pathophysiology of visual hallucinations in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789709

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  29 in total

1.  Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.

Authors:  Günes Kiziltan; Sibel Ozekmekçi; Sibel Ertan; Turan Ertan; Ethem Erginöz
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

2.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease.

Authors:  James M Shine; Glenda M Halliday; Moran Gilat; Elie Matar; Samuel J Bolitho; Maria Carlos; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2013-06-13       Impact factor: 5.038

Review 3.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

4.  Blindness, Psychosis, and the Visual Construction of the World.

Authors:  Thomas A Pollak; Philip R Corlett
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 5.  Visual hallucinations and the Charles Bonnet syndrome.

Authors:  Dominic H Ffytche
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

6.  Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.

Authors:  Jennifer G Goldman; Glenn T Stebbins; Vy Dinh; Bryan Bernard; Doug Merkitch; Leyla deToledo-Morrell; Christopher G Goetz
Journal:  Brain       Date:  2014-01-29       Impact factor: 13.501

Review 7.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 8.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

9.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 10.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.